NCT02530320View on ClinicalTrials.gov

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 25, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

March 31, 2020

Conditions
OligodendrogliomaOligoastrocytoma
Interventions
DRUG

Palbociclib

Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.

Trial Locations (11)

Unknown

Hospital Insular de Canarias, Las Palmas de Gran Canaria

Hospital Son Espases, Palma de Mallorca

Consorcio Hospitalario Provincial de Castellón, Castellon

Hospital Clínic de Barcelona, Barcelona

ICO Hospitalet, Barcelona

Hospital de León, León

Hospital 12 de Octubre, Madrid

Hospital Ramón y Cajal, Madrid

Hospital Regional de Málaga, Málaga

Hospital Virgen del Rocio, Seville

Hospital Universitario y Politécnico La Fe, Valencia

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Grupo Español de Investigación en Neurooncología

OTHER

NCT02530320 - Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | Biotech Hunter | Biotech Hunter